Stock comparison

BMYvsPFE

Bristol-Myers Squibb CovsPfizer Inc. Real data pulled from the alphactor.ai fundamentals pipeline — valuation, balance-sheet health, momentum, and analyst sentiment side by side.

BMY

Bristol-Myers Squibb Co

$59.02

+8.71%

Pharmaceuticals$117.4BNYSE

PFE

Pfizer Inc

$26.67

+3.17%

Pharmaceuticals$155.1BNYSE

60-day price, rebased to 100

BMY +8.73% · PFE +3.13%

Round-by-round

BMY 4·PFE 1· 1tie

EdgeBMY

Valuation upside

+2.90% vs -18.10% to DCF fair value

Tie

Balance-sheet strength

Altman Z 2.20 vs 2.15

EdgeBMY

Fundamental quality

Piotroski 9.00 vs 6.00 (of 9)

EdgeBMY

Growth + margins

Rule-of-40 26.40 vs 12.90

EdgeBMY

60-day momentum

+8.73% vs +3.13% price return

EdgePFE

Market-cap liquidity

$117.4B vs $155.1B

Verdict

Across6categories,BMYtakes the edge with4wins to1 (and 1 tie). Neither score is a buy signal on its own: run the full backtest and credibility tests on alphactor.ai before putting money on it.

Backtest a strategy onBMYorPFE

Point-in-time backtests, 8-layer credibility pipeline, conviction scoring — free to start.